Pacira(PCRX) Prnewswire·2025-02-18 10:45Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has adversely affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit is a response to a press release issued by Pacira on August 9, 2024, which announced the invalidation of its U.S. Patent No. 11,033,495 related to Exparel, a product that generates approximately 80% of the company's revenue [2] - Following the announcement, Pacira's stock price plummeted from 11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]